Critical evaluation of latanoprostene bunod in the treatment of glaucoma

References

• CharlsonMEde MoraesCGLinkANocturnal systemic hypotension increases the risk of glaucoma progressionOphthalmology20141212004201224869467
   PubMed Web of Science ®Google Scholar
• KamalDHitchingsRNormal tension glaucoma – a practical approachBr J Ophthalmol19988278358409924383
   PubMed Web of Science ®Google Scholar
• LeeAJMcCluskeyPClinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertensionClin Ophthalmol2010474176420689791
   PubMedGoogle Scholar
• SchwartzGFQuigleyHAAdherence and persistence with glaucoma therapySurv Ophthalmol200853Suppl 1S57S6819038625
   PubMed Web of Science ®Google Scholar
• NordstromBLFriedmanDSMozaffariEQuigleyHAWalkerAMPersistence and adherence with topical glaucoma therapyAm J Ophthalmol2005140459860616226511
   PubMed Web of Science ®Google Scholar
• SpoonerJJBullanoMFIkedaLIRates of discontinuation and change of glaucoma therapy in a managed care settingAm J Manag Care20028S262S27012188169
   PubMed Web of Science ®Google Scholar
• PatelSCSpaethGLCompliance in patients prescribed eyedrops for glaucomaOphthalmic Surg1995262332367651690
   PubMedGoogle Scholar
• CampbellJHSchwartzGFLaBountyBKowalskiJWPatelVDPatient adherence and persistence with topical ocular hypotensive therapy in real-world practice: a comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutionsClin Ophthalmol2014892793524868144
   PubMedGoogle Scholar
• KraussAHImpagnatielloFTorisCBOcular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical modelsExp Eye Res201193325025521396362
   PubMed Web of Science ®Google Scholar
• StamerWDAcottTSCurrent understanding of conventional outflow dysfunction in glaucomaCurr Opin Ophthalmol201223213514322262082
   PubMed Web of Science ®Google Scholar
• SharifNAKellyCRCriderJYAgonist activity of bimatoprost, travo-prost, latanoprost, unoprostone isopropyl ester and other prostaglandin analogs at the cloned human ciliary body FP prostaglandin receptorJ Ocul Pharmacol Ther200218431332412222762
   PubMed Web of Science ®Google Scholar
• Schlotzer-SchrehardtUZenkelMNüsingRMExpression and localization of FP and EP prostanoid receptor subtypes in human ocular tissuesInvest Ophthalmol Vis Sci20024351475148711980863
   PubMed Web of Science ®Google Scholar
• WeinrebRNLindseyJDMetalloproteinase gene transcription in human ciliary muscle cells with latanoprostInvest Ophthalmol Vis Sci200243371672211867589
   PubMed Web of Science ®Google Scholar
• SagaraTGatonDDLindseyJDGabeltBTKaufmanPLWeinrebRNTopical prostaglandin F2α treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathwayArch Ophthalmol199911779480110369592
   PubMed Web of Science ®Google Scholar
• OcklindAEffect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sectionsExp Eye Res19986721791919733584
   PubMed Web of Science ®Google Scholar
• WeinrebRNKashiwagiKKashiwagiFTsukaharaSLindseyJDProstaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cellsInvest Ophthalmol Vis Sci19973813277227809418730
   PubMed Web of Science ®Google Scholar
• WeinrebRNLindseyJDMarchenkoGMarchenkoNAngertMStronginAProstaglandin FP agonists alter metalloproteinase gene expression in scleraInvest Ophthalmol Vis Sci200445124368437715557445
   PubMed Web of Science ®Google Scholar
• AnthonyTLLindseyJDWeinrebRNLatanoprost’s effects on TIMP-1 and TIMP-2 expression in human ciliary muscle cellsInvest Ophthalmol Vis Sci200243123705371112454040
   PubMed Web of Science ®Google Scholar
• KimJWLindseyJDWangNWeinrebRNIncreased human scleral permeability with prostaglandin exposureInvest Ophthalmol Vis Sci20014271514152111381055
   PubMed Web of Science ®Google Scholar
• StjernschantzJSelénGOcklindAResulBEffects of latanoprost and related prostaglandin analoguesAlmAWeinrebRNUveoscleral Outflow: Biology and Clinical AspectsLondon, UKMosby International Limited19985772
   Google Scholar
• TorisCBGabeltBTKaufmanPLUpdate on the mechanism of action of topical prostaglandins for intraocular pressure reductionSurv Ophthalmol200853Suppl 1S107S12019038618
   PubMed Web of Science ®Google Scholar
• LimKSNauCBO’ByrneMMMechanism of action of bimato-prost, latanoprost, and travoprost in healthy subjects. A crossover studyOphthalmology20081155790795.e418452763
   PubMed Web of Science ®Google Scholar
• HinzBRöschSRamerRTammERBruneKLatanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanismFASEB J200519131929193116076963
   PubMed Web of Science ®Google Scholar
• StamerWDLeiYBoussommier-CallejaAOverbyDREthierCReNOS, a pressure-dependent regulator of intraocular pressureInvest Ophthalmol Vis Sci201152139438944422039240
   PubMed Web of Science ®Google Scholar
• KotikoskiHAlajuumaPMoilanenEComparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMPJ Ocul Pharmacol Ther2002181112311858611
   PubMed Web of Science ®Google Scholar
• ChumanHChumanTNao-iNSawadaAThe effect of L-arginine on intraocular pressure in the human eyeCurr Eye Res200020651151610980664
   PubMed Web of Science ®Google Scholar
• SchumanJSEricksonKNathansonJANitrovasodilator effects on intraocular pressure and outflow facility in monkeysExp Eye Res1994581991058157106
   PubMed Web of Science ®Google Scholar
• NathansonJANitrovasodilators as a new class of ocular hypotensive agentsJ Pharmacol Exp Ther199226039569651532035
   PubMed Web of Science ®Google Scholar
• WizemannAJWizemannVOrganic nitrate therapy in glaucomaAm J Ophthalmol19809011061096772033
   PubMed Web of Science ®Google Scholar
• ArnalJFDinh-XuanATPueyoMDarbladeBRamiJEndothelium-derived nitric oxide and vascular physiology and pathologyCell Mol Life Sci1999551078108710442089
   PubMed Web of Science ®Google Scholar
• DismukeWMMbadughaCCEllisDZNO-induced regulation of human trabecular meshwork cell volume and aqueous humor outflow facility involve the BKCa ion channelAm J Physiol Cell Physiol2008294C1378C138618385281
   PubMed Web of Science ®Google Scholar
• EllisDZDismukeWMChokshiBMCharacterization of soluble guanylate cyclase in NO-induced increases in aqueous humor outflow facility and in the trabecular meshworkInvest Ophthalmol Vis Sci20095041808181319074804
   PubMed Web of Science ®Google Scholar
• DismukeWMLiangJOverbyDRStamerWDConcentration-related effects of nitric oxide and endothelin-1 on human trabecular meshwork cell contractilityExp Eye Res2014120283524374036
   PubMed Web of Science ®Google Scholar
• RaoPVDengPSasakiYEpsteinDLRegulation of myosin light chain phosphorylation in the trabecular meshwork: role in aqueous humour outflow facilityExp Eye Res200580219720615670798
   PubMed Web of Science ®Google Scholar
• SchneemannADijkstraBGvan den BergTJKamphuisWHoyngPFNitric oxide/guanylate cyclase pathways and flow in anterior segment perfusionGraefes Arch Clin Exp Ophthalmol20022401193694112486517
   PubMed Web of Science ®Google Scholar
• EllisDZSharifNADismukeWMEndogenous regulation of human Schlemm’s canal cell volume by nitric oxide signalingInvest Ophthalmol Vis Sci201051115817582420484594
   PubMed Web of Science ®Google Scholar
• HeimarkRLKaocharSStamerWDHuman Schlemm’s canal cells express the endothelial adherens proteins, VE-cadherin and PECAM-1Curr Eye Res200225529930812658549
   PubMed Web of Science ®Google Scholar
• de KaterAWSpurr-MichaudSJGipsonIKLocalization of smooth muscle myosin-containing cells in the aqueous outflow pathwayInvest Ophthalmol Vis Sci19903123473532406217
   PubMed Web of Science ®Google Scholar
• KrupinTWeissABeckerBHolmbergNFritzCIncreased intraocular pressure following topical azide or niroprussideInvest Ophthalmol Vis Sci1977161110021007199556
   PubMed Web of Science ®Google Scholar
• ZamoraDOKielJWEpiscleral venous pressure responses to topical nitroprusside and N-Nitro-L-arginine methyl esterInvest Ophthalmol Vis Sci20105131614162019875657
   PubMed Web of Science ®Google Scholar
• FunkRHGehrJRohenJWShort-term hemodynamic changes in episcleral arteriovenous anastomoses correlate with venous pressure and IOP changes in the albino rabbitCurr Eye Res199615187938631208
   PubMed Web of Science ®Google Scholar
• SaekiTTsurugaHAiharaMAraieMRittenhouseKDose-response profile of PF-03187207 (PF-207) and peak IOP lowering response following single topical administration to FP receptor knockout mice vs wild type miceInvest Ophthalmol Vis Sci20095013 ARVO E-Abstract 4064
   Google Scholar
• KraussAHTorisCAKallbergMEOcular hypotensive activity of PF-03187207, a nitric oxide donating prostaglandin analog, in preclinical modelsInvest Ophthalmol Vis Sci200950 ARVO E-Abstract 1471
   Google Scholar
• CavetMEVollmerTRHarringtonKVanDerMeidKRichardsonMNO-induced regulation of primary human trabecular meshwork cell contractility by latanoprostene bunodInvest Ophthalmol Vis Sci20145513 ARVO E-Abstract 546
   Web of Science ®Google Scholar
• CavetMEVollmerTRHarringtonKLVanDerMeidKRichardsonMERegulation of endothelin-1-induced trabecular meshwork cell contractility by latanoprostene bunodInvest Ophthalmol Vis Sci20155664108411626114488
   PubMed Web of Science ®Google Scholar
• SjöquistBStjernschantzJOcular and systemic pharmacokinetics of latanoprost in humansSurv Ophthalmol200247Suppl 1S6S1212204697
   PubMed Web of Science ®Google Scholar
• ResulBStjernschantzJSelénGBitoLStructure-activity relationships and receptor profiles of some ocular hypotensive prostanoidsSurv Ophthalmol199741Suppl 2S47S529154276
   PubMed Web of Science ®Google Scholar
• StjernschantzKSelénGSjöquistBResulBPreclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogueAdv Prostaglandin Thromboxane Leukot Res1995235135187732899
   PubMedGoogle Scholar
• OrihashiMShimaYTsunekiHKimuraIPotent reduction of intraocular pressure by nipradilol plus latanoprost in ocular hypertensive rabbitsBiol Pharm Bull2005281656815635165
   PubMed Web of Science ®Google Scholar
• WoodwardDFBurkeJAWilliamsLSProstaglandin F2 alpha effects on intraocular pressure negatively correlate with FP-receptor stimulationInvest Ophthalmol Vis Sci1989308183818422759797
   PubMed Web of Science ®Google Scholar
• AraieMSforzoliniBSVittitowJWeinrebRNEvaluation of the effect of latanoprostene bunod ophthalmic solution, 0.024% in lowering intraocular pressure over 24 h in healthy Japanese subjectsAdv Ther201532111128113926563323
   PubMed Web of Science ®Google Scholar
• AraieMScassellati-SforzoliniBNgumahQVittitowJWeinrebREfficacy of Vesneo™ (Latanoprostene bunod ophthalmic solution, 0.024%) in Lowering Intraocular Pressure Over 24 hours in Healthy Japanese SubjectsPoster presented at: 6th World Glaucoma CongressJune 6–9, 2015Hong Kong, China Abstract P-S-056
   Google Scholar
• AraieMOngTScassellati-SforzoliniBNgumahQVittitowJLWeinrebRNEfficacy of latanoprostene bunod ophthalmic solution, 0.024%, in lowering intraocular pressure over 24-hours in normal Japanese subjects (KRONUS)Invest Ophthalmol Vis Sci20145513 ARVO E-Abstract 548
   Web of Science ®Google Scholar
• WeinrebRNOngTScassellati SforzoliniBA randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER studyBr J Ophthalmol201599673874525488946
   PubMed Web of Science ®Google Scholar
• WeinrebRNOngTScassellatiBA prospective randomized, multicenter, single-masked, parallel, dose ranging (VOYAGER) study to compare the safety and efficacy of BOL-303259-X to latanoprost in subjects with open-angle glaucoma or ocular hypertensionPaper presented at: 23rd Annual Meeting of the American Glaucoma Society2013Vancouver, Canada
   Google Scholar
• WeinrebRNA prospective randomized, multicenter, single-masked, parallel, dose ranging (VOYAGER) study to compare the safety and efficacy of BOL-303259-X to latanoprost in subjects with open-angle glaucoma or ocular hypertension2013World Glaucoma Congress Paper presentation
   Google Scholar
• KatzLJKaufmanPOngTScassellati-SforzoliniBVittitowJLatanoprostene bunod 0.024% significantly reduces and maintains mean diurnal intra-ocular pressure (IOP) compared to latanoprost 0.005% in subjects with open angle glaucoma or ocular hypertensionInvest Ophthalmol Vis Sci20135413 ARVO E-Abstract 460
   Google Scholar
• IwaseASuzukiYAraieMThe prevalence of primary open-angle glaucoma in Japanese: the Tajimi StudyOphthalmology200411191641164815350316
   PubMed Web of Science ®Google Scholar
• QuarantaLKatsanosARussoARivaI24-hour intraocular pressure and ocular perfusion pressure in glaucomaSurv Ophthalmol2013581264123217586
   PubMed Web of Science ®Google Scholar
• DeokuleSWeinrebRNRelationships among systemic blood pressure, intraocular pressure, and open-angle glaucomaCan J Ophthalmol200843330230718493272
   PubMed Web of Science ®Google Scholar
• NickensDMandemaJCourtneyRRaberSBosworthCA model-based dose-response meta-analysis of single agent intraocular pressure (IOP) therapies used to evaluate efficacy of a potential new therapy (PF-03187207) in glaucoma patientsInvest Ophthalmol Vis Sci20095013 ARVO E-Abstract 2479
   Google Scholar
• BosworthCFZhangMCourtneyRRaberSEvelethDBeekmanMEfficacy and safety of PF-03187207, a novel nitric oxide donating prostaglandin F2-alpha analogue, vs latanoprost in hypertensive eyesInvest Ophthalmol Vis Sci20095013 ARVO E-Abstract 2481
   Google Scholar
• RaberSZhangMCourtneyREvelethDComparison of once-daily morning or evening dosing of PF-03187207, a novel nitric oxide donating prostaglandin f2-alpha analogue, vs latanoprost in hypertensive eyesFlorence, ItalyEuropean Glaucoma Society2010 Abstract P3.1
   Google Scholar
• LiuJHKVittitowJLNgumahQWeinrebRNEfficacy of Latanoprostene bunod ophthalmic solution 0.024% compared with timolol maleate ophthalmic solution 0.5% in lowering IOP over 24 hours in Subjects with open angle glaucoma or ocular hypertension (CONSTELLATION)Invest Ophthalmol Vis Sci20145513 ARVO E-Abstract
   Web of Science ®Google Scholar
• LiuJVittitowJSforzoliniBWeinrebREffects of latanoprostene bunod compared with timolol maleate on ocular perfusion pressure in subjects with open-angle glaucoma or ocular hypertension2015American Glaucoma Society Abstract PO015
   Google Scholar
• Scassellati SforzoliniBVittitowJWeinrebREfficacy of Vesneo™ (latanoprostene bunod ophthalmic solution, 0.024%) compared with timolol maleate ophthalmic solution 0.5% in subjects with open-angle glaucoma or ocular hypertension2015World Glaucoma Congress Abstract RF-T-03-07
   Google Scholar
• LiuJVittitowJScassellati SforzoliniBWeinrebROcular perfusion pressure effects of Vesneo™ (latanoprostene bunod ophthalmic solution, 0.024%) timolol maleate ophthalmic solution 0.5% in subjects with open-angle glaucoma or ocular hypertension2015World Glaucoma Congress Abstract P-S-074
   Google Scholar
• WeinrebRNScassellati SforzoliniBVittitowJLiebmannJLatanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO StudyOphthalmology2016123596597326875002
   PubMed Web of Science ®Google Scholar
• VittitowJLiebmannJMWeinrebRThe effect of latanoprostene bunod 0.024% vs timolol maleate 0.5% on lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension: the APOLLO Study2016American Glaucoma Society Abstract PO086
   Google Scholar
• VittitowJLLiebmannJMKaufmanPLMedeirosFAMartinKRWeinrebRNLong-term efficacy and safety of latanoprostene bunod 0.024% for intraocular pressure lowering in patients with open-angle glaucoma or ocular hypertension: APOLLO and LUNAR studiesInvest Ophthalmol Vis Sci201657 ARVO E-Abstract 3030
   Google Scholar
• KaufmanPLLiebmannJMVittitowJLWeinrebRNIntegrated efficacy of latanoprostene bunod 0.024% vs timolol maleate 0.5% for intraocular pressure lowering in patients with open-angle glaucoma or ocular hypertension: APOLLO and LUNAR studiesInvest Ophthalmol Vis Sci201657 ARVO E-Abstract 3036
   Web of Science ®Google Scholar
• MedeirosFAMartinKRPeaceJScassellati SforzoliniBVittitowJLWeinrebRNComparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: the LUNAR StudyAm J Ophthalmol Epub2016519
   Web of Science ®Google Scholar
• PeaceJHMedeirosFAMartinKRVittitowJLWeinrebRNEfficacy of latanoprostene bunod 0.024% vs timolol maleate 0.5% for intraocular pressure lowering in patients with open angle glaucoma or ocular hypertension: the LUNAR studyInvest Ophthalmol Vis Sci201657 ARVO E-Abstract 3035
   Google Scholar
• KawaseKVittitowJLYamamotoTAraieMLong-term safety and intraocular pressure lowering efficacy of latanoprostene bunod 0.024% in Japanese subjects with open angle glaucoma or ocular hypertension: the JUPITER studyInvest Ophthalmol Vis Sci201657 ARVO E-Abstract 3037
   Google Scholar
• HenryJCPeaceJHStewartJAStewartWCEfficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapyClin Ophthalmol2008261362119668762
   PubMedGoogle Scholar
• GuenounJMBaudouinCRatPPaulyAWarnetJMBrignole-BaudouinFIn vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cellsInvest Ophthalmol Vis Sci2005462444245015980234
   PubMed Web of Science ®Google Scholar
• ParrishRKPalmbergPSheuWPXLT Study GroupA comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter studyAm J Ophthalmol2003135568870312719078
   PubMed Web of Science ®Google Scholar
• BaudouinCDetrimental effect of preservatives in eyedrops: implications for the treatment of glaucomaActa Ophthalmol200886771672618537937
   PubMed Web of Science ®Google Scholar
• BerkeSJPAP: New concerns for prostaglandin useRev Ophthalmol2012191070
   Google Scholar
• NelsonPAspinallPPapasouliotisOWortonBO’BrienCQuality of life in glaucoma and its relationship with visual functionJ Glaucoma200312213915012671469
   PubMed Web of Science ®Google Scholar
• SkalickySGoldbergIDepression and quality of life in patients with glaucoma: a cross-sectional analysis using the Geriatric Depression Scale-15, assessment of function related to vision, and the Glaucoma Quality of Life-15J Glaucoma200817754655118854731
   PubMed Web of Science ®Google Scholar
• Diniz-FilhoAAbeRYChoHJBaigSGracitelliCPMedeirosFAFast visual field progression Is associated with depressive symptoms in patients with glaucomaOphthalmology2016123475475926920097
   PubMed Web of Science ®Google Scholar
• ZimmermanTJStewartWCLatanoprost Axis Study GroupIntraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatmentsJ Ocul Pharmacol Ther200319540541514583133
   PubMed Web of Science ®Google Scholar
• StrykerJEBeckADPrimoSAAn exploratory study of factors influencing glaucoma treatment adherenceJ Glaucoma2010191667220075676
   PubMed Web of Science ®Google Scholar
• TsaiJCMcClureCARamosSESchlundtDGPichertJWCompliance barriers in glaucoma: a systematic classificationJ Glaucoma200312539339814520147
   PubMed Web of Science ®Google Scholar
• TaylorSAGalbraithSMMillsRPCauses of non-compliance with drug regimens in glaucoma patients: a qualitative studyJ Ocul Pharmacol Ther200218540140912419091
   PubMed Web of Science ®Google Scholar
• LaceyJCateHBroadwayDCBarriers to adherence with glaucoma medications: a qualitative research studyEye (Lond)200923492493218437182
   PubMed Web of Science ®Google Scholar
• FriedmanDSHahnSRGelbLDoctor-patient communication, health-related beliefs, and adherence in glaucoma results from the glaucoma adherence and persistency Study (GAPS)Ophthalmology200811581320132718321582
   PubMed Web of Science ®Google Scholar
• FeldmanRMConjunctival hyperemia and the use of topical prostaglandins in glaucoma and ocular hypertensionJ Ocul Pharmacol Ther2003191233512648301
   PubMed Web of Science ®Google Scholar
• AbelsonMBNetlandPAChapinMJSwitching patients with glaucoma or ocular hypertension from dual therapy to monotherapy: evaluation of brimonidine as a modelAdv Ther200118628229711841198
   PubMed Web of Science ®Google Scholar
• PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol20028641842311914211
   PubMed Web of Science ®Google Scholar
• KahookMYNoeckerRJEvaluation of adherence to morning versus evening glaucoma medication dosing regimensClin Ophthalmol200711798319668470
   PubMedGoogle Scholar
• FordBAGooiMCarlssonACrichtonACMorning dosing of once-daily glaucoma medication is more convenient and may lead to greater adherence than evening dosingJ Glaucoma20132211421946541
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol20021206701713 discussion 829–83012049574
   PubMed Web of Science ®Google Scholar
• LeskeMCHeijlAHusseinMFactors for glaucoma progression and the effect of treatment: the early manifest glaucoma trialArch Ophthalmol2003121485612523884
   PubMed Web of Science ®Google Scholar